On the heels of a move to reduce its viral vector manufacturing workforce, Thermo Fisher is beefing up its biologics production business through a $4.1 billion acquisition. The buyout target is ...
Highly Complementary to Thermo Fisher’s Bioproduction Business and Strengthens Offering in the High Growth Bioprocessing Market Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher ...